Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of Neovacs' IFNa-Kinoid immunotherapy in patients with systemic lupus erythematosus

Next Previous
X
Search
Trial Profile

Phase III study of Neovacs' IFNa-Kinoid immunotherapy in patients with systemic lupus erythematosus

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha kinoid (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Mar 2023 According to a Neovacs media release, Neovacs and Biosense Global LLC have signed a new partnership agreement to Kinoid product in the treatment of lupus and this agreement allows resumption of clinical trials in China, fully supported by Biosense Global. Biosense Global will now bear the entire costs of these new clinical trials for the mutual benefit of both partners
    • 02 Oct 2019 According to a Neovacs media release, consultations with the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) will be scheduled in a second phase.
    • 02 Oct 2019 According to a Neovacs media release, based on the result of IFN alpha KinoId obtained with LLDAS in Phase IIb (profile 244217) and the approval of the LLDAS approach by the scientific community, Neovacs is currently consulting the Agence Nationale de Securite du Medicament et des produits de sante (ANSM) (French National Agency for the Safety of Medicines and Health Products) on the adoption of LLDAS as a primary criterion for the Phase III. The conclusions are expected in the Q1 of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top